SB 258585 hydrochloride
CAS No. 1216468-02-8
SB 258585 hydrochloride ( SB258585 )
产品货号. M10810 CAS No. 1216468-02-8
SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
规格 | 价格/人民币 | 库存 | 数量 |
5MG | ¥7857 | 有现货 |
|
50MG | ¥16038 | 有现货 |
|
100MG | ¥20250 | 有现货 |
|
200MG | 获取报价 | 有现货 |
|
500MG | 获取报价 | 有现货 |
|
1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称SB 258585 hydrochloride
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM.
-
产品描述SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM, >160-fold selectivity over other 5-HT receptor subtypes; also is an inhibitor of HCV entry in liver-derived cell lines as well as primary hepatocytes, modulates localization of the coreceptor tight junction protein claudin-1 (CLDN1) in a 5-HT6-independent manner, induces intracellular accumulation of CLDN1.
-
同义词SB258585
-
通路Endocrinology/Hormones
-
靶点5-HT Receptor
-
受体5-HT Receptor
-
研究领域——
-
适应症——
化学信息
-
CAS Number1216468-02-8
-
分子量523.81
-
分子式C18H23ClIN3O3S
-
纯度>98% (HPLC)
-
溶解度——
-
SMILESCN1CCN(CC1)C2=C(C=CC(=C2)NS(=O)(=O)C3=CC=C(C=C3)I)OC.Cl
-
化学全称4-Iodo-N-[4-methoxy-3-(4-methyl-1-piperazinyl)phenyl]benzenesulfonamide hydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Hirst WD, et al. Br J Pharmacol. 2000 Aug;130(7):1597-605.
2. Riva L, et al. J Virol. 2018 Apr 27;92(10). pii: e01982-17.
2. Riva L, et al. J Virol. 2018 Apr 27;92(10). pii: e01982-17.
产品手册
关联产品
-
PRX933 hydrochloride
PRX933 hydrochloride is an agonist of 5-HT2c receptor.
-
8-Hydroxy-DPAT hydro...
8-Hydroxy-DPAT hydrobromide (8-OH-DPAT hydrobromide) is a potent and selective 5-HT1A agonist with a pIC50 of 8.19. 8-Hydroxy-DPAT hydrobromide has a selectivity of almost 1000 fold for a subtype of the 5-HT1 binding site.
-
Mirtazapine
Mirtazapine is an antidepressant introduced by Organon International in 1996 used for the treatment of moderate to severe depression.